Robert Marsh, MD
Hematology & Oncology · Gainesville, VANPI 1730157371
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,404 of the $4,741 with a category attached, or 71.8%. 43 manufacturers reported payments, led by Beigene USA, Inc. at 27.6% of the total. Reporting peaked in 2024 at $3,133 and has fallen 78.9% since, to $662 in 2025.
Across 150 payments — averaging $31.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$1K
- Novartis$542
- Johnson & Johnson$452
- Pfizer$199
- AstraZeneca$178
- Merck$147
- plus $2K from 37 others
Across 10 payments — averaging $23,483 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$128K
- Merck$55K
- AstraZeneca$52K
What the payments were for
- Consulting fees$1,23826%
- Food & beverage$3,40472%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$1,238
How this compares
$4,741 in reported general payments places this provider in the 70th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 32 | $593,340 |
| JakafiRuxolitinib Phosphate | 30 | $576,126 |
| ImbruvicaIbrutinib | 29 | $385,098 |
| CalquenceAcalabrutinib Maleate | 24 | $352,000 |
| TasignaNilotinib Hcl | 14 | $286,191 |
| PomalystPomalidomide | 13 | $247,997 |
| Lenalidomide | 21 | $223,807 |
| VenclextaVenetoclax | 19 | $219,301 |
| TagrissoOsimertinib Mesylate | 13 | $205,821 |
| EliquisApixaban | 114 | $129,776 |
| XareltoRivaroxaban | 36 | $39,740 |
| OrgovyxRelugolix | 11 | $29,445 |
| Imatinib Mesylate | 19 | $24,797 |
| Deferasirox | 16 | $7,877 |
| Exemestane | 46 | $5,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $80 | $593,34032 claims |
| Incyte CorporationJakafi | $98 | $576,12630 claims |
| AstraZenecaCalquence, Tagrisso | $178 | $557,82237 claims |
| NovartisTasigna | $542 | $286,19114 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $74 | $247,99713 claims |
| AbbVieVenclexta | $44 | $219,30119 claims |
| PfizerEliquis | $199 | $129,776114 claims |
| Johnson & JohnsonXarelto | $452 | $39,74036 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $16 | $29,44511 claims |
| Lilly USA, LLCOlanzapine | $28 | $37736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Gainesville
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.